Figure 1 | Scientific Reports

Figure 1

From: Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment

Figure 1

ASO-T3 conjugate structure and function. (a) Schematic process of ASO-T3 synthesis. (b–c) Thyroid hormone receptor reporter activity in HEK293 cells treated with T3, NNMT-ASO-T3 (NAT3) (b) or ApoB-ASO-T3 (c) with or without the lysosome inhibitor chloroquine (CHQ). (d) ApoB mRNA levels in Hepa1-6 hepatoma cells treated with ApoB-ASO (AA) or AAT3. (e) NNMT mRNA levels in adipose tissue treated NNMT-ASO (NA) or NAT3. n = 4–6 per group; *p < 0.05 vs controls (Con), #p < 0.05 vs NAT3 or AAT3.

Back to article page